SK279767B6 - Farmaceutická kombinácia na použitie pri ošetrovan - Google Patents

Farmaceutická kombinácia na použitie pri ošetrovan Download PDF

Info

Publication number: SK279767B6
Authority: SK; Slovakia
Prior art keywords: formula; component; pharmaceutical; acid; compound
Prior art date: 1991-03-06

Application number

SK951-93A

Other languages

English (en)

Slovak (sk)

Other versions

SK95193A3 (en

Inventor

George R. Painter Iii

Phillip A. Furman

Original Assignee

The Wellcome Foundation Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-06

Filing date

1992-03-05

Publication date

1999-03-12

1992-03-05 Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited

1994-01-12 Publication of SK95193A3 publication Critical patent/SK95193A3/sk

1999-03-12 Publication of SK279767B6 publication Critical patent/SK279767B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
230000009385 viral infection Effects 0.000 title claims description 10
208000036142 Viral infection Diseases 0.000 title claims description 9
238000011282 treatment Methods 0.000 claims abstract description 19
229960004413 flucytosine Drugs 0.000 claims abstract description 17
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 17
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 14
241000725303 Human immunodeficiency virus Species 0.000 claims description 12
241000282414 Homo sapiens Species 0.000 claims description 6
238000011321 prophylaxis Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
150000003833 nucleoside derivatives Chemical class 0.000 abstract description 3
206010038997 Retroviral infections Diseases 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 59
150000001875 compounds Chemical class 0.000 description 39
239000004480 active ingredient Substances 0.000 description 38
239000000306 component Substances 0.000 description 21
238000000034 method Methods 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
238000009472 formulation Methods 0.000 description 14
208000030507 AIDS Diseases 0.000 description 12
230000000840 anti-viral effect Effects 0.000 description 12
239000003826 tablet Substances 0.000 description 12
229960002555 zidovudine Drugs 0.000 description 12
239000004615 ingredient Substances 0.000 description 11
239000002585 base Substances 0.000 description 10
239000002775 capsule Substances 0.000 description 10
-1 ester salt Chemical class 0.000 description 10
239000000243 solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
150000002148 esters Chemical class 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000008101 lactose Substances 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
125000002252 acyl group Chemical group 0.000 description 7
230000000694 effects Effects 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
229940069328 povidone Drugs 0.000 description 7
230000002195 synergetic effect Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000007788 liquid Substances 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
239000013543 active substance Substances 0.000 description 5
230000036436 anti-hiv Effects 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
239000000725 suspension Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229940125904 compound 1 Drugs 0.000 description 3
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical class C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 2
CCZMQYGSXWZFKI-UHFFFAOYSA-N 1-chloro-4-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=C(OP(Cl)(Cl)=O)C=C1 CCZMQYGSXWZFKI-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
239000002841 Lewis acid Substances 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000012025 fluorinating agent Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
150000007517 lewis acids Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000155 melt Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
229940102001 zinc bromide Drugs 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
GUTQTHVYODVCQP-UHFFFAOYSA-N 2,2-diethoxyethanethiol Chemical compound CCOC(CS)OCC GUTQTHVYODVCQP-UHFFFAOYSA-N 0.000 description 1
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
QKRMFCXDTFLKKT-UHFFFAOYSA-N 2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O QKRMFCXDTFLKKT-UHFFFAOYSA-N 0.000 description 1
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
208000031504 Asymptomatic Infections Diseases 0.000 description 1
208000034048 Asymptomatic disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
208000027814 HTLV-2 infection Diseases 0.000 description 1
208000005599 HTLV-I Infections Diseases 0.000 description 1
208000007687 HTLV-II Infections Diseases 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
206010033885 Paraparesis Diseases 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
MKSGJSLVQHXINJ-HUUCEWRRSA-N [(2r,5r)-5-(4-acetamido-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@@H]1O[C@@H](COC(=O)C=2C=CC=CC=2)SC1 MKSGJSLVQHXINJ-HUUCEWRRSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
125000005251 aryl acyl group Chemical group 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical class N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000012503 blood component Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229940099563 lactobionic acid Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007905 soft elastic gelatin capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000008719 thickening Effects 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
SMBZJSVIKJMSFP-UHFFFAOYSA-N trifluoromethyl hypofluorite Chemical compound FOC(F)(F)F SMBZJSVIKJMSFP-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

SK951-93A 1991-03-06 1992-03-05 Farmaceutická kombinácia na použitie pri ošetrovan SK279767B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919104740A GB9104740D0 (en)	1991-03-06	1991-03-06	Antiviral nucleoside combination
PCT/GB1992/000389 WO1992015309A1 (en)	1991-03-06	1992-03-05	Antiviral nucleoside combination

Publications (2)

Publication Number	Publication Date
SK95193A3 SK95193A3 (en)	1994-01-12
SK279767B6 true SK279767B6 (sk)	1999-03-12

Family

ID=10691101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK951-93A SK279767B6 (sk)	1991-03-06	1992-03-05	Farmaceutická kombinácia na použitie pri ošetrovan

Country Status (26)

Country	Link
US (2)	US5234913A (uk)
EP (1)	EP0574457B1 (uk)
JP (1)	JP3442773B2 (uk)
KR (1)	KR100225986B1 (uk)
AT (1)	ATE185483T1 (uk)
AU (1)	AU668860B2 (uk)
CA (1)	CA2105487C (uk)
CZ (1)	CZ283185B6 (uk)
DE (1)	DE69230140T2 (uk)
DK (1)	DK0574457T3 (uk)
ES (1)	ES2138969T3 (uk)
GB (1)	GB9104740D0 (uk)
GR (1)	GR3032299T3 (uk)
HK (1)	HK1004189A1 (uk)
HU (1)	HU219492B (uk)
IE (1)	IE920702A1 (uk)
IL (1)	IL101145A (uk)
MY (1)	MY108638A (uk)
NZ (1)	NZ241842A (uk)
PT (1)	PT100199B (uk)
RU (1)	RU2110993C1 (uk)
SK (1)	SK279767B6 (uk)
TW (1)	TW199861B (uk)
UA (1)	UA29429C2 (uk)
WO (1)	WO1992015309A1 (uk)
ZA (1)	ZA921660B (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6903224B2 (en)	1988-04-11	2005-06-07	Biochem Pharma Inc.	Substituted 1,3-oxathiolanes
SE464168B (sv) *	1989-07-19	1991-03-18	Bo Fredrik Oeberg	Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US6346627B1 (en)	1990-02-01	2002-02-12	Emory University	Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) *	1990-02-01	1999-06-22	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) *	1990-12-05	1999-07-20	Emory University	Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) *	1991-03-06	2004-11-02	Emory University	Therapeutic nucleosides
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
US5817667A (en) *	1991-04-17	1998-10-06	University Of Georgia Research Foudation	Compounds and methods for the treatment of cancer
DE69206876T3 (de) *	1991-05-16	2004-08-12	Glaxo Group Ltd., Greenford	Nukleosidanalogen enthaltende Antiviren-Zubereitungen
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
US6177435B1 (en)	1992-05-13	2001-01-23	Glaxo Wellcome Inc.	Therapeutic combinations
US20020120130A1 (en) *	1993-09-10	2002-08-29	Gilles Gosselin	2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
AU2119695A (en) *	1994-03-16	1995-10-03	Tanox Biosystems, Inc.	Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
IL115156A (en) *	1994-09-06	2000-07-16	Univ Georgia	Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) *	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en)	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
DE69636734T2 (de) *	1995-06-07	2007-10-18	Emory University	Nucleoside mit anti-hepatitis b virus wirksamkeit
DE69727240T2 (de) *	1996-06-25	2004-11-25	Glaxo Group Ltd., Greenford	Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
BR9709951A (pt) *	1996-06-25	1999-08-10	Glaxo Group Ltd	Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado uso de éster de tetraidro-3-furilanila do ácido 3s[3r(1r,2s)]-[3-[[4-amino-enil)sulfonil](2-metilpropil]-2-hiroxi-1-fenilmetil)propil]-carbânico, zidovudino,e (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenteno-1-metanol e pacote para paciente
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
CA2287370C (en) *	1997-03-19	2010-02-09	Emory University	Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
EP0986375A2 (en)	1997-04-07	2000-03-22	Triangle Pharmaceuticals Inc.	Use of mkc-442 in combination with other antiviral agents
US6040434A (en) *	1997-12-01	2000-03-21	Inaba; Tadanobu	Aldehyde oxidase inhibitors for treatment of aids
JP2002518452A (ja) *	1998-06-24	2002-06-25	エモリユニバーシティ	Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
AU771779B2 (en)	1998-08-12	2004-04-01	Emory University	Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en)	1998-10-09	2005-12-27	Gilead Sciences, Inc.	Non-homogeneous systems for the resolution of enantiomeric mixtures
PT1382343E (pt)	1998-11-02	2010-03-10	Gilead Sciences Inc	Terapia de combinação para tratamento do vírus da hepatite b
US6436948B1 (en)	2000-03-03	2002-08-20	University Of Georgia Research Foundation Inc.	Method for the treatment of psoriasis and genital warts
WO2002070518A1 (en) *	2001-03-01	2002-09-12	Triangle Pharmaceuticals, Inc.	Polymorphic and other crystalline forms of cis-ftc
UA93354C2 (uk) *	2004-07-09	2011-02-10	Гилиад Сайенсиз, Инк.	Місцевий противірусний препарат

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4874751A (en) *	1985-03-16	1989-10-17	Burroughs Wellcome Co.	Antibacterial treatment
ATE81978T1 (de) *	1985-03-16	1992-11-15	Wellcome Found	Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
JPH07116042B2 (ja) *	1985-05-15	1995-12-13	ザウエルカムフアウンデ−シヨンリミテツド	ヌクレオシド化合物
NZ222695A (en) *	1986-11-29	1990-03-27	Ueno Seiyaku Oyo Kenkyujo Kk	Synergistic antiviral compositions
US5159067A (en) *	1987-01-28	1992-10-27	University Of Georgia Research Foundation Inc.	5'-Diphosphohexose nucleoside pharmaceutical compositions
US4837311A (en) *	1987-06-22	1989-06-06	Hoffman-La Roche Inc.	Anti-retroviral compounds
US5047407A (en) *	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) *	1988-04-11	1991-08-20	Iaf Biochem International, Inc.	4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) *	1988-04-11	1991-09-25	Iaf Biochem Int	1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
WO1990014079A1 (en) *	1989-05-15	1990-11-29	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Method of treatment of hepatitis
US5071983A (en) *	1989-10-06	1991-12-10	Burroughs Wellcome Co.	Therapeutic nucleosides
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
IT1249019B (it) *	1990-06-28	1995-02-11	Lamberti S P A L	Emulsione acquosa di resine filmogene per la finitura di pelli, cuoio e croste di pelle e relativo procedimento di applicazione
DE69122264T2 (de) *	1990-11-13	1997-02-06	Biochem Pharma Inc., Laval, Quebec	Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
IL100502A (en) *	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
DE69206876T3 (de) *	1991-05-16	2004-08-12	Glaxo Group Ltd., Greenford	Nukleosidanalogen enthaltende Antiviren-Zubereitungen

1991
- 1991-03-06 GB GB919104740A patent/GB9104740D0/en active Pending
1992
- 1992-03-05 RU RU93045710A patent/RU2110993C1/ru active
- 1992-03-05 JP JP50556492A patent/JP3442773B2/ja not_active Expired - Lifetime
- 1992-03-05 PT PT100199A patent/PT100199B/pt not_active IP Right Cessation
- 1992-03-05 EP EP92905707A patent/EP0574457B1/en not_active Expired - Lifetime
- 1992-03-05 CA CA002105487A patent/CA2105487C/en not_active Expired - Lifetime
- 1992-03-05 ZA ZA921660A patent/ZA921660B/xx unknown
- 1992-03-05 KR KR1019930702626A patent/KR100225986B1/ko not_active IP Right Cessation
- 1992-03-05 WO PCT/GB1992/000389 patent/WO1992015309A1/en active IP Right Grant
- 1992-03-05 DK DK92905707T patent/DK0574457T3/da active
- 1992-03-05 UA UA94051479A patent/UA29429C2/uk unknown
- 1992-03-05 HU HU9302496A patent/HU219492B/hu unknown
- 1992-03-05 MY MYPI92000357A patent/MY108638A/en unknown
- 1992-03-05 IL IL10114592A patent/IL101145A/en not_active IP Right Cessation
- 1992-03-05 SK SK951-93A patent/SK279767B6/sk not_active IP Right Cessation
- 1992-03-05 US US07/846,367 patent/US5234913A/en not_active Expired - Lifetime
- 1992-03-05 ES ES92905707T patent/ES2138969T3/es not_active Expired - Lifetime
- 1992-03-05 IE IE070292A patent/IE920702A1/en not_active IP Right Cessation
- 1992-03-05 CZ CS931836A patent/CZ283185B6/cs not_active IP Right Cessation
- 1992-03-05 TW TW081101695A patent/TW199861B/zh active
- 1992-03-05 AT AT92905707T patent/ATE185483T1/de active
- 1992-03-05 DE DE69230140T patent/DE69230140T2/de not_active Expired - Lifetime
- 1992-03-05 NZ NZ241842A patent/NZ241842A/en not_active IP Right Cessation
- 1992-03-05 AU AU13512/92A patent/AU668860B2/en not_active Expired
1993
- 1993-04-27 US US08/054,548 patent/US6107288A/en not_active Expired - Lifetime
1998
- 1998-04-22 HK HK98103372A patent/HK1004189A1/xx not_active IP Right Cessation
1999
- 1999-12-30 GR GR990403387T patent/GR3032299T3/el unknown

Also Published As

Publication number	Publication date
IE920702A1 (en)	1992-09-09
CZ183693A3 (en)	1994-06-15
CA2105487C (en)	2002-09-24
HU9302496D0 (en)	1993-11-29
JP3442773B2 (ja)	2003-09-02
TW199861B (uk)	1993-02-11
DE69230140D1 (de)	1999-11-18
AU1351292A (en)	1992-10-06
NZ241842A (en)	1994-08-26
JPH06506199A (ja)	1994-07-14
US6107288A (en)	2000-08-22
GB9104740D0 (en)	1991-04-17
PT100199B (pt)	1999-06-30
UA29429C2 (uk)	2000-11-15
CZ283185B6 (cs)	1998-01-14
US5234913A (en)	1993-08-10
DE69230140T2 (de)	2000-04-06
HUT72460A (en)	1996-04-29
DK0574457T3 (da)	2000-04-17
EP0574457A1 (en)	1993-12-22
ES2138969T3 (es)	2000-02-01
ZA921660B (en)	1993-09-06
ATE185483T1 (de)	1999-10-15
IL101145A (en)	1996-08-04
SK95193A3 (en)	1994-01-12
IL101145A0 (en)	1992-11-15
CA2105487A1 (en)	1992-09-07
KR100225986B1 (ko)	1999-10-15
HK1004189A1 (en)	1998-11-20
MY108638A (en)	1996-10-31
EP0574457B1 (en)	1999-10-13
AU668860B2 (en)	1996-05-23
PT100199A (pt)	1993-07-30
HU219492B (hu)	2001-04-28
WO1992015309A1 (en)	1992-09-17
GR3032299T3 (en)	2000-04-27
RU2110993C1 (ru)	1998-05-20

Legal Events

Date	Code	Title	Description
2012-05-03	MK4A	Patent expired	Expiry date: 20120305

Publication	Publication Date	Title
SK279767B6 (sk)	1999-03-12	Farmaceutická kombinácia na použitie pri ošetrovan
RU2116789C1 (ru)	1998-08-10	Способ ингибирования вирусных инфекций гепатита в
JP2954357B2 (ja)	1999-09-27	ジドブジン、１５９２ｕ８９および３ｔｃまたはｆｔｃの相乗的組み合わせ
JPH07116042B2 (ja)	1995-12-13	ヌクレオシド化合物
US5376644A (en)	1994-12-27	Treatment of adenovical infections with 3'-fluoro-5-halo uracil compounds
KR100331714B1 (ko)	2002-11-01	디데옥시뉴클레오티드유사체를이용한바이러스감염의치료방법
FI91763B (fi)	1994-04-29	Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi
EP0639971B1 (en)	1999-09-22	Therapeutic combinations
US20080187580A1 (en)	2008-08-07	Therapeutic nucleosides
HU199865B (en)	1990-03-28	Process for production of healing nucleosides and medical compositions containing them
CA1336821C (en)	1995-08-29	Therapeutic nucleosides